Shoulder Innovations, Inc. (SI)
NYSE:SI
Want to see SI full AI Analyst Report?
SI Stock Chart & Stats
$14.54
<$0.01(0.07%)
At close: 4:00 PM EDT
$14.54
<$0.01(0.07%)
Day’s Range― - ―
52-Week Range$10.92 - $19.79
Previous Close$15.29
Volume91.20K
Average Volume (3M)130.13K
Market Cap
$384.69M
Enterprise Value$376.18M
Total Cash (Recent Filing)$108.54M
Total Debt (Recent Filing)$15.01M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Sep 15, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding20,738,226
10 Day Avg. Volume53,279
30 Day Avg. Volume130,135
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.90
Price to Sales (P/S)6.23
P/FCF Ratio-8.19
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue6.98
Enterprise Value/Gross Profit9.25
Enterprise Value/Ebitda-9.14
Forecast
1Y Price Target
$21.00Price Target Upside44.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$67.34M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Gross MarginSustained high revenue growth with a 77.7% gross margin demonstrates attractive, scalable unit economics that can absorb sales and R&D investments. Management raised 2026 revenue guidance and cites cost‑down programs, indicating margins can remain durable as volumes and surgeon adoption expand.
Surgeon Adoption & Product EcosystemRapid surgeon adoption, growing customer funnels and a broadening product set (full launch of I-135RFX and expanding registry data) create durable competitive advantages: clinical evidence, sticky workflows and ecosystem lock‑in that support sustainable share gains in shoulder arthroplasty.
Balance Sheet & Liquidity CushionA strong cash balance and low leverage give the company financial flexibility to fund inventory builds, commercialization and R&D without immediate refinancing. This buffer reduces short-term funding risk and supports a deliberate path to breakeven while scaling commercial operations.
Bears Say
Widening Losses & Negative ReturnsOperating and net losses have widened materially, producing deeply negative returns on equity. Persistent losses consume capital and delay shareholder value creation; unless operating expenses moderate or revenue growth accelerates further, losses will continue to erode the balance sheet over time.
Persistent Negative Cash Flow & Accelerating BurnConsistent negative operating and free cash flow increases reliance on external financing and raises funding risk if markets tighten. Accelerating burn driven by inventory and working capital further pressures runway, making sustained growth contingent on either improved cash generation or continued capital access.
High SG&A And R&D Investment PressureElevated selling and R&D spend is funding expansion and product development but compresses margins while losses persist. If commercial scaling or product adoption slows, fixed and variable cost burdens could delay breakeven and necessitate sharper cost cuts or additional funding, reducing optionality.
Shoulder Innovations, Inc. News
SI FAQ
What was Shoulder Innovations, Inc.’s price range in the past 12 months?
Shoulder Innovations, Inc. lowest stock price was $10.92 and its highest was $19.79 in the past 12 months.
What is Shoulder Innovations, Inc.’s market cap?
Shoulder Innovations, Inc.’s market cap is $384.69M.
When is Shoulder Innovations, Inc.’s upcoming earnings report date?
Shoulder Innovations, Inc.’s upcoming earnings report date is Sep 15, 2026 which is in 86 days.
How were Shoulder Innovations, Inc.’s earnings last quarter?
Shoulder Innovations, Inc. released its earnings results on May 13, 2026. The company reported -$0.41 earnings per share for the quarter, the consensus estimate of -$0.41 by $0.
Is Shoulder Innovations, Inc. overvalued?
According to Wall Street analysts Shoulder Innovations, Inc.’s price is currently Undervalued.
Does Shoulder Innovations, Inc. pay dividends?
Shoulder Innovations, Inc. does not currently pay dividends.
What is Shoulder Innovations, Inc.’s EPS estimate?
Shoulder Innovations, Inc.’s EPS estimate is -0.47.
How many shares outstanding does Shoulder Innovations, Inc. have?
Shoulder Innovations, Inc. has 20,738,226 shares outstanding.
What happened to Shoulder Innovations, Inc.’s price movement after its last earnings report?
Shoulder Innovations, Inc. reported an EPS of -$0.41 in its last earnings report, expectations of -$0.41. Following the earnings report the stock price went up 15.225%.
Which hedge fund is a major shareholder of Shoulder Innovations, Inc.?
Currently, no hedge funds are holding shares in SI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shoulder Innovations, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (44.43% Upside)
$21.00 (44.43% Upside)
Hedge Fund Trend
Decreased
By 482.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $78.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-35.31%
Trailing 12-Months
Asset Growth
178.77%
Trailing 12-Months
Company Description
Shoulder Innovations, Inc.
Shoulder Innovations, Inc. is a medical technology firm that engineers and produces sophisticated devices. The company is particularly recognized for designing an innovative shoulder replacement system. Co-founded in 2009 by Stephen B. Gunther and Michael DeVries, its main corporate office is situated in Grand Rapids, Michigan.
SI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operating and commercial momentum: sizable revenue and volume growth, improving gross margins, accelerating surgeon adoption and meaningful product and technology milestones (I-135 full launch, N22 limited release, >500 patients in registry, and a progressing robotic partnership). These positives were offset by increased operating expenses and larger net and adjusted EBITDA losses as the company invests to scale, a Q1 cash burn driven by inventory and working capital, and some seasonality and ASP/mix variability risk embedded in the updated guidance. Overall, management expressed high conviction in the trajectory and raised full-year guidance while noting near-term investment-related impacts.View all SI earnings summariesSI Stock 12 Month Forecast
Average Price Target
$21.00
▲(44.43% Upside)
Technical Analysis
Ownership Overview
58.63% Insiders
7.77% Mutual Funds
7.87% Other Institutional Investors
21.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---